Boston area experts recently commented on the digital technologies they’re using in a pilot of a surgical home hospital in bariatric surgery at Brigham and Women’s Hospital.

Researchers at Brigham and Women’s Hospital recently published data from an open-label phase 1b/2a trial suggesting induction therapy with low-dose IL-2 is safe for patients with ulcerative colitis and suppresses the disease.

In a retrospective real-world study, Brigham and Women’s Hospital researchers demonstrated that tofacitinib and ustekinumab are equally effective for achieving steroid-free clinical remission of ulcerative colitis at 12 and 52 weeks.

Researchers at Brigham and Women’s Hospital, MIT, and California Institute of Technology have devised a system for localizing and tracking wireless microdevices inside the GI tract in real-time and in non-clinical settings, with millimeter-scale spatial resolution and no need for X-ray radiation.

Brigham and Women’s Hospital recently determined how epithelial cells promote Th17 cell generation in response to bacterial colonization as a step toward better understanding the treatment—and even prevention—of chronic inflammatory diseases.

After decades as a practicing surgeon, Pardon R. Kenney, MD, MS, was ready to step away from the operating room—but not from medicine or his love of teaching. In the Brigham’s new Section of Surgical Educators, he now shares the knowledge he has amassed with new medical students, residents, and attending physicians.

Brigham and Women’s Hospital is honored to participate in the 2023 Digestive Disease Week (DDW) annual meeting on May 6-9 in Chicago, IL. This is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.